Liquid Chromatography Mass Spectrometry for Quantifying Plasma Lysophospholipids: Potential Biomarkers for Cancer Diagnosis

Murph, Mandi M.; Tanaka, Tamotsu; Pang, Jihai; Felix, Edward; Liu, Shuying; Trost, Rosanne; Godwin, Andrew K.; Newman, Robert A.; Mills, Gordon B.

doi:10.1016/s0076-6879(07)33001-2

Cited by 88 publications

(77 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This pattern is in good accord with the literature (7,9,11,16 ). Quantification was achieved by the addition of 5 different concentrations of standards for S1P, SA1P, LPA 16:0, LPA 18:0, LPA 18:1, LPA 18:2, and LPA 20:4 to samples of human plasma (Table 1).…”

supporting

confidence: 87%

“…Several methods lack coelution of the internal standard and the analyte, which is necessary to help compensate for potential matrix effects or for varying ionization efficiency due to mobile-phase gradients (7,10,11,14 ). Laborious sample preparation (8,15 ), large sample volumes (8,(11)(12)(13), time-consuming derivatization procedures (15 ), and a lack of sufficient validation (8 -11 ) exclude these methods from routine analysis. Only one methodology exists for combined measurement of LPA and S1P (11 ).…”

mentioning

confidence: 99%

“…Laborious sample preparation (8,15 ), large sample volumes (8,(11)(12)(13), time-consuming derivatization procedures (15 ), and a lack of sufficient validation (8 -11 ) exclude these methods from routine analysis. Only one methodology exists for combined measurement of LPA and S1P (11 ). We describe a simple and rapid LC-MS/MS method for quantifying S1P, sphinganine 1-phosphate (SA1P), and LPA species.…”

mentioning

confidence: 99%

See 2 more Smart Citations

High-Throughput Analysis of Sphingosine 1-Phosphate, Sphinganine 1-Phosphate, and Lysophosphatidic Acid in Plasma Samples by Liquid Chromatography–Tandem Mass Spectrometry

2009

View full text Add to dashboard Cite

BACKGROUND:Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are ubiquitous lipid messengers found in the blood and most cell types. Both lysophospholipids are ligands of G protein-coupled receptors and mediate important physiological processes. Moreover, lysophospholipids are potential biomarkers for various diseases, including atherosclerosis and cancer. Because existing methodologies are of limited value for systematic evaluations of S1P and LPA in clinical studies, we developed a fast and simple quantification method that uses liquid chromatography-tandem mass spectrometry (LC-MS/MS).

show abstract

supporting

confidence: 87%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

High-Throughput Analysis of Sphingosine 1-Phosphate, Sphinganine 1-Phosphate, and Lysophosphatidic Acid in Plasma Samples by Liquid Chromatography–Tandem Mass Spectrometry

2009

View full text Add to dashboard Cite

show abstract

“…Binding affinity of LPA for apoA-I and L-4F was determined as described previously (26). Serum LPA levels were determined as described previously (56).…”

Section: Methodsmentioning

confidence: 99%

Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer

Su¹,

Kozak²,

Imaizumi³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

183

186

View full text Add to dashboard Cite

We examined whether reduced levels of Apolipoprotein A-I (apoA-I) in ovarian cancer patients are causal in ovarian cancer in a mouse model. Mice expressing a human apoA-I transgene had (i) increased survival (P < 0.0001) and (ii) decreased tumor development (P < 0.01), when compared with littermates, following injection of mouse ovarian epithelial papillary serous adenocarcinoma cells (ID-8 cells). ApoA-I mimetic peptides reduced viability and proliferation of ID8 cells and cis-platinum-resistant human ovarian cancer cells, and decreased ID-8 cell-mediated tumor burden in C57BL/6J mice when administered subcutaneously or orally. Serum levels of lysophosphatidic acid, a well-characterized modulator of tumor cell proliferation, were significantly reduced (>50% compared with control mice, P < 0.05) in mice that received apoA-I mimetic peptides (administered either subcutaneously or orally), suggesting that binding and removal of lysophosphatidic acid is a potential mechanism for the inhibition of tumor development by apoA-I mimetic peptides, which may serve as a previously unexplored class of anticancer agents.

show abstract

“…A similar phenomenon has been observed in other malignant tumors. The abnormal levels of LPCs are due to binding and activation by the specific cellsurface G protein-coupled receptors, which initiate cell growth, proliferation, and survival pathways [75].…”

Section: Ovarian Cancermentioning

confidence: 99%

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Zhao

Cheng

Vaziri

et al. 2014

Clinical Biochemistry

120

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oObjectives: Metabonomics is a powerful and promising analytic tool that allows assessment of global lowmolecular-weight metabolites in biological systems. It has a great potential for identifying useful biomarkers for early diagnosis, prognosis and assessment of therapeutic interventions in clinical practice. The aim of this review is to provide a brief summary of the recent advances in UPLC-based metabonomic approach for biomarker discovery in a variety of diseases, and to discuss their significance in clinical chemistry.Design and methods: All the available information on UPLC-based metabonomic applications for discovering biomarkers of diseases were collected via a library and electronic search (using Web of Science, Pubmed, ScienceDirect, Springer, Google Scholar, etc.).Results: Metabonomics has been used in clinical chemistry to identify and evaluate potential biomarkers and therapeutic targets in various diseases affecting the liver (hepatocarcinoma and liver cirrhosis), lung (lung cancer and pneumonia), gastrointestinal tract (colorectal cancer) and urogenital tract (prostate cancer, ovarian cancer and chronic kidney disease), as well as metabolic diseases (diabetes) and neuropsychiatric disorders (Alzheimer's disease and schizophrenia), etc.Conclusions: The information provided highlights the potential value of determination of endogenous lowmolecular-weight metabolites and the advantages and potential drawbacks of the application of UPLC-based metabonomics in clinical setting.

show abstract

Liquid Chromatography Mass Spectrometry for Quantifying Plasma Lysophospholipids: Potential Biomarkers for Cancer Diagnosis

Cited by 88 publications

References 46 publications

High-Throughput Analysis of Sphingosine 1-Phosphate, Sphinganine 1-Phosphate, and Lysophosphatidic Acid in Plasma Samples by Liquid Chromatography–Tandem Mass Spectrometry

High-Throughput Analysis of Sphingosine 1-Phosphate, Sphinganine 1-Phosphate, and Lysophosphatidic Acid in Plasma Samples by Liquid Chromatography–Tandem Mass Spectrometry

Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Contact Info

Product

Resources

About